Migration of Lipid Nanoparticles away from the Deltoid muscle and into Vital Organs was Planned According to BioNTech CEO Ugur Sahin
Harold Saive
Contrary to the official narrative, in September of 2020.
BioNTech CEO Ugur Sahin claimed:
"For the Covid-19 candidate vaccine we have chosen lipid
nanoparticles that promote migration from the muscle cells
into lymph nodes."
The following CHD article addresses the migration of the lipid
nanoparticles into the lymph nodes but also "circulated
throughout the body and accumulated in large concentrations in
organs and tissues, including the spleen, bone marrow, liver,
adrenal glands and — in “quite high concentrations” — in the
ovaries."
_____________________
(CHD 6/17/2021) Inventor of mRNA Technology: Vaccine Causes Lipid
Nanoparticles to Accumulate in ‘High Concentrations’ in Ovaries
On the “Dark Horse Podcast,” Dr. Robert Malone, creator of mRNA
vaccine technology, said the COVID vaccine lipid nanoparticles —
which tell the body to produce the spike protein — leave the
injection site and accumulate in organs and tissues.
Prior to the Japanese study’s disclosure, the public was led to
believe by regulators and vaccine developers that the spike
protein produced by mRNA COVID vaccines stayed in the shoulder
where it was injected and was not biologically active — even
though regulators around the world had a copy of the study which
showed otherwise.
https://childrenshealthdefense.org/defender/mrna-technology-covid-vaccine-lipid-nanoparticles-accumulate-ovaries/
_____________________
Coronona Investigative Committee - Prof. Ulrike Kammerer
(Whistleblower)
Links to articles and documents provided in video pinned comment
https://odysee.com/@Corona-Investigative-Committee:5/session-82-en:1?r=8cSGjqEoyncQGynLZgG9WAbC61LaBPpT&t=15742
Highlights:
- (LIE #1) mRNA lipid nanoparticles not designed to stay in arms
as claimed by propaganda. The lipid NP's were always intended to
deploy to lymph nodes.
- (LIE #2) Pfizer lied when they claimed vials should remain at
-80 deg C. This lie was to expedite vaccine deployment. Currently
there is no requirement for deep refrigeration of this product
- Listen for the comment about microscopy image chracterized as
"Cells with arms that move".
- Deliberate suppression of the immune system creates an
auto-immune condition described as "VAIDS" "Vaccine Induced
Auto-immune Deficiency)
German: (2 SEP 2020) Teil des Covid-19-Impfstoffes
könnte aus Österreich kommen
English: (2 SEP 2020) Part of the Covid-19
vaccine could come from Austria
https://www.diepresse.com/5861311/teil-des-covid-19-impfstoffes-konnte-aus-osterreich-kommen
Quote German to English (Google)
Depending on how these lipid nanoparticles are constructed on the
surface, they behave differently. BioNTech CEO Ugur Sahin:
"For the Covid-19 candidate vaccine we have chosen lipid
nanoparticles that promote migration from the muscle cells into
lymph nodes. Dendritic (antigen-presenting; note) cells then
present the resulting S-protein to the immune system. We
have in According to the early data published so far, both a
strong antibody reaction of the B cells and the formation of
specific CD4-positive and CD8-positive T cells were observed.The
CD4 cells promote a protective immune response, the CD8 cells
remain in the blood for a long time inhibit the virus from
multiplying in infected cells. "
___________________________________________
Google Translation - German-English
Teil des Covid-19-Impfstoffes könnte aus Österreich kommen
English: "Part of the Covid-19 vaccine could come from
Austria"
https://www.diepresse.com/5861311/teil-des-covid-19-impfstoffes-konnte-aus-osterreich-kommen
The Lower Austrian biotech company Polymun is involved in the
Pfizer and BioNTech corona vaccine project.
More than 170 biotech companies worldwide are competing for
Covid-19 vaccines. Polymun from Klosterneuburg is involved in one
of the projects that is currently the most advanced worldwide - by
US pharmaceutical company Pfizer and German biotechnology company
BioNTech. It produces important parts for the candidate vaccine
doses for the clinical studies, including the phase III study that
has already started. Pfizer boss Albert Bourla, BioNTech CEO
Ugur Sahin and Polymun managing director Dietmar Katinger
explained this in an interview with the APA.
"We are one of the world's largest vaccine manufacturers and have
been active in this field for decades. We have been working with
BioNTech (Mainz; note) since 2018 on an mRNA vaccine against
influenza. When it became clear in February of this year that the
If the newly identified SARS-CoV-2 virus strain could develop into
what we now call the Covid-19 pandemic, we have also teamed up
with BioNTech for a coronavirus vaccination and prioritized the
project, "said Pfizer CEO Bourla on Tuesday as part of a short
visit to the Lower Austrian biotech company Polymun, which emerged
from the research of BOKU biotech pioneer Hermann Katinger and is
now managed by his son, Dietmar Katinger.
The decision was made very quickly. Ugur Sahin, CEO of the
German BioNTech, which pursues numerous development projects
for drugs (e.g. oncologics) and for vaccines based on mRNA and
other technologies: "The agreement with Pfizer on the Covid-19
project was concluded quickly and rather informally. We did
Initially, 20 vaccine candidates were developed and tested to
prevent infection with the virus. The preclinical tests were
carried out on mice and rhesus monkeys. Our lead candidate
BNT162b2 has been in clinical phase II / III (efficacy, safety on
a large scale; note) since July. "
These are virus genetic material fragments that are already
suitable for the expression of SARS-CoV-2. "This mRNA leads to
the production of the harmless, entire spike (S) protein of
the coronavirus in human cells. These pieces of RNA are 3800 base
pairs long and consist of around 1200 amino acids," explained
Sahin. In a phase I / II clinical study, two injections of the
vaccine candidate with an interval of 21 days showed a stronger
immune response than in people who "naturally" got and survived a
SARS-CoV-2 infection. "We want to generate a stronger and
longer-lasting protective immune response in the vaccinated."
"Master the generation of liposomes"
In principle, there are several advantages to mRNA vaccines. "The
vaccine is injected into a muscle. The body's own cells then
produce the virus S-protein themselves, against which the immune
system generates a protective response. You do not need to produce
antigens in cell cultures, etc., there can be no contamination,"
he explained Expert who has been working with RNA technology
since 1998 and worked at the University of Mainz before
BioNTech was founded.
But for a vaccine, the mRNA has to be packaged in suitable
transport vehicles. This is where Polymun comes in. "We
have mastered the production of liposomes or lipid nanoparticles
with GMP (pharmaceutical; note) quality. We can transfer
production from the laboratory to larger quantities for industrial
vaccine production," said Dietmar Katinger.
Depending on how these lipid nanoparticles are constructed on the
surface, they behave differently. Sahin: "For the
Covid-19 candidate vaccine we have chosen lipid nanoparticles
that promote migration from the muscle cells into lymph nodes.
Dendritic (antigen-presenting; note) cells then present the
resulting S-protein to the immune system. We have in
According to the early data published so far, both a strong
antibody reaction of the B cells and the formation of specific
CD4-positive and CD8-positive T cells were observed.The CD4 cells
promote a protective immune response, the CD8 cells remain in the
blood for a long time inhibit the virus from multiplying in
infected cells. "
Development continues
In the case of the BioNTech candidate vaccine, Polymun expert
Andreas Wagner constructed lipid nanoparticles with a size of 50
to one hundred nanometers (nanometers: billionths of a meter;
note) that can only be made visible under an electron
microscope. Katinger: "We produced the BioNTech vaccine
candidates for the clinical trials."
The development continues. The Polymun managing director: "We are
working on producing one million cans per batch and are also
making the technology available to others who will also start
production for BioNTech / Pfizer."
In the meantime, we are eagerly awaiting the results of the
efficacy study with BNT162b2. Pfizer CEO Albert Bourla:
"Our Phase III studies with BioNTech are currently running at 125
clinics in the USA, Brazil and Argentina. More than 20,000 of the
planned 30,000 test subjects have already been enrolled. 15,000
will receive the candidate vaccines, 15,000 a placebo. If we
have enough 'events' (infections with SARS-CoV-2; note), the study
will be 'unblinded'. So far, nobody knows who is receiving what.
Then we will know more about the vaccine candidate and its
properties. "
Results expected in October
For the vaccinations - two injections 21 days apart - a dose of 30
micrograms is used. According to the results from the initial
investigations (phase I / II), this also leads to a good immune
response in older people. The candidate vaccine has been well
tolerated so far. Mild feverish reactions in about 20 percent of
the subjects were observed. That is in line with expectations.
The results of the crucial phase III study, the results of
which will be included in the approval of the vaccine, should
possibly be available in October. Bourla: "The approval
authority will receive the data as soon as it is available.
Approval will probably go very quickly if the results of the
efficacy test are positive. We hope to be able to produce up to a
hundred million doses of the vaccine this year, around year 1
next. 3 billion. Pfizer has three manufacturing facilities in
the US and one in Europe, plus two BioNTech manufacturing
facilities in Germany.
Another production site will be Polymun in Klosterneuburg. Despite
all efforts worldwide, the Pfizer CEO is cautious: "The need for
Covid-19 vaccines will initially be greater than production."
______________
See TOWN SQUARE NEWS Updates: https://groups.google.com/g/town-square-news
